Hanoi, Vietnam & Fort Collins, CO – January 3, 2013 – The Company for Vaccine and Biological
Production No.1 (VABIOTECH) and Inviragen, Inc. today announced a licensing agreement by which
VABIOTECH will acquire rights to Inviragen’s proprietary Japanese encephalitis (JE) technology to
produce a cell-derived vaccine.

SAN FRANCISCO, Dec. 27, 2012 /PRNewswire/ — goBalto, Inc. (www.gobalto.com) announced
today that it closed a $12 million round of venture financing, led by EDBI, the global investment
arm of Singapore’s Economic Development Board, with participation from new investor
Qualcomm Life Fund, a $100 million investment allocation that is managed by Qualcomm
Ventures, Qualcomm’s investment group.

Singapore, 18 December 2012 – Ezion Holdings Limited (“Ezion” and together with its subsidiaries the
“Group”), a leading Singapore headquartered, offshore logistics support service provider, announced
the subscription of approximately 14.3 million new ordinary shares (the “New Shares”) by strategic
investor, EDB Investments Pte Ltd (“EDBI”), the corporate investment arm of Singapore’s Economic
Development Board, for approximately S$19 million.

SANTA CLARA, Calif. — December 22, 2011— Global ophthalmic company OptiMedica Corp.

SAN DIEGO – December 7, 2011 – Sotera Wireless, Inc. today announced the completion of a
$12.2 million Series D financing led by Singapore-based global fund, EDBI. The round also
included new investor Cerner Capital and existing investors Sanderling Ventures, Qualcomm
Ventures, Intel Capital and West Health Investment Fund

Smart Device Media Co-Founder and Former Ziff Davis CEO, Jason Young to lead the
Combined Company

Fort Collins, CO – December 7, 2011 – Inviragen, Inc. presented results of the Phase 1 clinical trial of
DENVax conducted in Colombia at the annual American Society of Tropical Medicine and Hygiene
(ASTMH) meeting today. In this randomized, placebo-controlled study of 96 healthy adults, DENVax was
safe and well tolerated and induced significant neutralizing antibody responses to all four dengue virus
subtypes. The most frequent adverse events reported were transient local injection site reactions

Campaign for Singapore Tourism Board: China’s First Rich Media Campaign to
Follow International MRAID Standards

NEW YORK & EMERYVILLE, CA ‐‐ Forest Laboratories, Inc. (NYSE: FRX), an international
pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that they
have entered into an agreement for the development and commercialization of a fixed
dosed combination (FDC) of Namenda XR® (memantine HCl extended release) and
donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of
the Alzheimer’s type in the United States. Under the agreement, Forest and Adamas will
collaborate on the development of the FDC and Forest will have exclusive US
commercialization rights.

London, 16 November 2011: mBlox, a leader in mobile consumer interaction and payments, today
announces mBlox Entrust™, a suite of mobile payment solutions for both in-app and mobile web
payments that makes paying for goods and services over mobile and tablet devices simpler, easier and
safer than ever before. mBlox Entrust delivers secure, resilient, easy-to-use payment services for
consumers purchasing on the move.